Pfizer tracks infant safety for new pneumonia vaccine
NCT ID NCT06622109
Summary
This study is monitoring the safety of the Prevenar 20 vaccine in real-world use in Japan. It is enrolling about 1,100 infants aged 2 to 6 months who are getting this vaccine for the first time. Researchers will track any side effects the infants experience after each of their four scheduled shots.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Pfizer
Tokyo, 151-8589, Japan
Conditions
Explore the condition pages connected to this study.